Payment overview · 2025
General Payments
$844.33
49 reported records · 16 companies
Healthcare provider profile · identity verified
James H Walker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PENDLETON, SC · NPI 1871533505
Verified facts
What the public records show
CMS Open Payments records show James H Walker, M.D. received $844.33 in general payments during 2025 across 49 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $247.50 | 29.3% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.54 | 17.8% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.18 | 10.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $80.20 | 9.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.79 | 5.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.10 | 5.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.58 | 4.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.44 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.53 | 2.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.38 | 2.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.78 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.91 | 2.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.04 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.17 | 1.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.16 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.03 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $844.33 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $247.50 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $100.46 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.36 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.18 | 8 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $63.92 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.58 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 113 |
| Gabapentin | Gabapentin | 397 | 122 |
| Losartan Potassium | Losartan Potassium | 397 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 355 | 114 |
| Omeprazole | Omeprazole | 332 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 86 |
| Diclofenac Sodium | Diclofenac Sodium | 263 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 254 | 67 |
| Glimepiride | Glimepiride | 250 | 72 |
| Montelukast Sodium | Montelukast Sodium | 248 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 229 | 39 |
| Metformin Hcl | Metformin Hcl | 222 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 219 | 73 |
| Trazodone Hcl | Trazodone Hcl | 200 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 192 | 59 |
| Furosemide | Furosemide | 188 | 60 |
| Methylprednisolone | Methylprednisolone | 188 | 143 |
| Celecoxib | Celecoxib | 179 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 82 |
| Carvedilol | Carvedilol | 170 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 165 | 48 |
| Spironolactone | Spironolactone | 158 | 48 |
| Meloxicam | Meloxicam | 146 | 44 |
| Levofloxacin | Levofloxacin | 145 | 121 |
| Lisinopril | Lisinopril | 144 | 49 |
| Tramadol Hcl | Tramadol Hcl | 132 | 39 |
| Finasteride | Finasteride | 123 | 38 |
| Clonazepam | Clonazepam | 121 | 19 |
| Pregabalin | Pregabalin | 120 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 35 |
| Cefdinir | Cefdinir | 116 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 40 |
| Eliquis | Apixaban | 112 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 31 |
| Allopurinol | Allopurinol | 106 | 33 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 104 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 80 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 103 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 30 |
| Simvastatin | Simvastatin | 102 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 68 |
| Lorazepam | Lorazepam | 92 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 90 | 71 |
| Azithromycin | Azithromycin | 88 | 64 |
| Mounjaro | Tirzepatide | 88 | 15 |
| Metformin Hcl Er | Metformin Hcl | 87 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 84 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 77 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 20 |
| Prednisone | Prednisone | 76 | 49 |
| Potassium Chloride | Potassium Chloride | 74 | 20 |
| Fenofibrate | Fenofibrate | 72 | 21 |
| Memantine Hcl | Memantine Hcl | 72 | 21 |
| Trulicity | Dulaglutide | 70 | 11 |
| Mupirocin | Mupirocin | 69 | 38 |
| Bupropion Xl | Bupropion Hcl | 68 | 33 |
| Doxepin Hcl | Doxepin Hcl | 68 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 25 |
| Warfarin Sodium | Warfarin Sodium | 67 | 13 |
| Jardiance | Empagliflozin | 63 | 20 |
| Mirtazapine | Mirtazapine | 62 | 20 |
| Nortriptyline Hcl | Nortriptyline Hcl | 62 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 12 |
| Cilostazol | Cilostazol | 57 | 19 |
| Sertraline Hcl | Sertraline Hcl | 57 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 33 |
| Myrbetriq | Mirabegron | 56 | 15 |
| Buspirone Hcl | Buspirone Hcl | 54 | 14 |
| Alendronate Sodium | Alendronate Sodium | 53 | 17 |
| Aripiprazole | Aripiprazole | 52 | 15 |
| Estradiol | Estradiol | 50 | 16 |
| Synthroid | Levothyroxine Sodium | 48 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 17 |
| Ibuprofen | Ibuprofen | 47 | 17 |
| Propranolol Hcl | Propranolol Hcl | 47 | 15 |
| Benazepril Hcl | Benazepril Hcl | 46 | 14 |
| Famotidine | Famotidine | 46 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 15 |
| Naproxen | Naproxen | 46 | 20 |
| Baclofen | Baclofen | 44 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 37 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 13 |
| Valacyclovir | Valacyclovir Hcl | 43 | 22 |
| Acarbose | Acarbose | 42 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 20 |
| Tolterodine Tartrate | Tolterodine Tartrate | 41 | 15 |
| Cephalexin | Cephalexin | 39 | 32 |
| Diazepam | Diazepam | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 12 |
| Colestipol Hcl | Colestipol Hcl | 37 | 15 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 37 | 15 |
| Valsartan | Valsartan | 37 | 14 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Nystatin | Nystatin | 36 | 22 |
| Metronidazole | Metronidazole | 33 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Topiramate | Topiramate | 29 | 14 |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 24 |
| Betamethasone Valerate | Betamethasone Valerate | 27 | 18 |
| Trimethoprim | Trimethoprim | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Sucralfate | Sucralfate | 24 | 16 |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Toprol Xl | Metoprolol Succinate | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Indapamide | Indapamide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Oxazepam | Oxazepam | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Altace | Ramipril | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | 11 |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $844.33 · 49 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ACCRUFER, AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Kerendia, MOUNJARO, NUPLAZID, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, VYEPTI, WATCHMAN Access System, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error